Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Thomas C. Abshire MD

Thomas C. Abshire MD profile photo picture


Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology and Oncology - Pediatrics
Program: Hematology

Research Experience

  • Blood Coagulation Disorders, Inherited
  • Clinical Trial
  • Hemostasis
  • Thrombosis
  • von Willebrand Diseases
  • Clinical trials in hemostasis and thrombosis including laboratory evaluation, therapeutic intervention and new product development.
  • Evaluation of mild bleeding disorders in children including the role of the clinical history and in clinical trials in Von Willebrand Disease.
  • Clinical Expertise

  • Blood Coagulation Disorders
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Thrombosis
  • von Willebrand Diseases
  • Publications (65)

  • Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy. (Gill JC, Conley SF, Johnson VP, Christopherson PA, Haberichter SL, Diaz CD, Strong TC, Zhang J, Simpson P, Abshire TC, Montgomery RR, Flood VH) Blood Adv 2020 01 14;4(1):100-105 PMID: 31905240 PMCID: PMC6960478 SCOPUS ID: 2-s2.0-85078147321 01/07/2020       4 Citations
  • Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. (Warren BB, Jacobson L, Kempton C, Buchanan GR, Recht M, Brown D, Leissinger C, Shapiro AD, Abshire TC, Manco-Johnson MJ, Joint Outcome Study Group Investigators) Haemophilia 2019 Sep;25(5):867-875 PMID: 31115111 PMCID: PMC7273872 05/23/2019       1 Citation
  • Von Willebrand disease in the United States: perspective from the Zimmerman program. (Flood VH, Abshire TC, Christopherson PA, Friedman KD, Cox Gill J, Montgomery RR, Haberichter SL, Zimmerman Program Investigators) Ann Blood 2018 Jan;3 PMID: 30135959 PMCID: PMC6100783 08/24/2018    
  • Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. (Holm E, Carlsson KS, Lövdahl S, Lail AE, Abshire TC, Berntorp E) Haemophilia 2018 Jul;24(4):628-633 PMID: 29626372 04/08/2018       3 Citations
  • Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. (Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2017 10;15(10):1971-1976 PMID: 28795528 PMCID: PMC5716470 08/11/2017       6 Citations
  • Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. (Kulkarni R, Presley RJ, Lusher JM, Shapiro AD, Gill JC, Manco-Johnson M, Koerper MA, Abshire TC, DiMichele D, Hoots WK, Mathew P, Nugent DJ, Geraghty S, Evatt BL, Soucie JM) Haemophilia 2017 Mar;23(2):207-214 PMID: 27813214 PMCID: PMC5354941 11/05/2016       19 Citations
  • Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay. (Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2016 10;14(10):1931-1940 PMID: 27501440 PMCID: PMC5083216 10/28/2016       6 Citations
  • Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. (Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR) Blood 2016 05 19;127(20):2481-8 PMID: 26862110 PMCID: PMC4874228 SCOPUS ID: 2-s2.0-84974556876 02/11/2016       47 Citations
  • Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations. (Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2015 Jun;13(6):1036-42 PMID: 25780857 PMCID: PMC4512234 03/18/2015       7 Citations
  • Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. (Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E) Blood Coagul Fibrinolysis 2015 Jun;26(4):383-8 PMID: 25688461 02/18/2015       21 Citations
  • Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. (Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH, Hemophilia Inhibitor Research Study Investigators, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2015 Jan;13(1):47-53 PMID: 25354263 PMCID: PMC4383171 10/30/2014       17 Citations
  • A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. (Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT, Haemophilia Inhibitor Research Study Investigators) Haemophilia 2014 Mar;20(2):230-7 PMID: 24261612 PMCID: PMC4519821 11/23/2013       23 Citations
  • Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. (Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2013 Jul;11(7):1300-9 PMID: 23601690 PMCID: PMC4477744 04/23/2013       33 Citations
  • Evaluation for bleeding disorders in suspected child abuse. (Anderst JD, Carpenter SL, Abshire TC, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics) Pediatrics 2013 Apr;131(4):e1314-22 PMID: 23530182 03/27/2013       52 Citations
  • Evaluating for suspected child abuse: conditions that predispose to bleeding. (Carpenter SL, Abshire TC, Anderst JD, Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics) Pediatrics 2013 Apr;131(4):e1357-73 PMID: 23530171 03/27/2013       30 Citations
  • No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. (Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR) Blood 2013 May 02;121(18):3742-4 PMID: 23520336 PMCID: PMC3643771 SCOPUS ID: 2-s2.0-84879719268 03/23/2013       20 Citations
  • Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). (Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E, VWD PN) Haemophilia 2013 Jan;19(1):76-81 PMID: 22823000 PMCID: PMC4514514 07/25/2012       71 Citations
  • Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. (Kempton CL, Abshire TC, Deveras RA, Hoots WK, Gill JC, Kessler CM, Key NS, Konkle BA, Kuriakose P, Macfarlane DE, Bergman G) Haemophilia 2012 Sep;18(5):798-804 PMID: 22512291 04/20/2012       43 Citations
  • TAFI made stickier. (Abshire T) Blood 2012 Apr 12;119(15):3380-1 PMID: 22500053 04/14/2012       1 Citation
  • Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. (Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, Hemophilia Inhibitor Research Study Investigators) J Thromb Haemost 2012 Jun;10(6):1055-61 PMID: 22435927 PMCID: PMC4477703 03/23/2012       65 Citations
  • VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. (Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR) Blood 2012 Mar 01;119(9):2135-40 PMID: 22197721 PMCID: PMC3311248 SCOPUS ID: 2-s2.0-84857720362 12/27/2011       60 Citations
  • A community-based partnership to promote information infrastructure for bleeding disorders. (Aschman DJ, Abshire TC, Shapiro AD, Lusher JM, Forsberg AD, Kulkarni R) Am J Prev Med 2011 Dec;41(6 Suppl 4):S332-7 PMID: 22099355 12/07/2011       3 Citations
  • F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. (Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W, Hemophilia Inhibitor Research Study Investigators) Haemophilia 2012 May;18(3):375-82 PMID: 22103590 11/23/2011       81 Citations
  • The principal results of the International Immune Tolerance Study: a randomized dose comparison. (Hay CR, DiMichele DM, International Immune Tolerance Study) Blood 2012 Feb 09;119(6):1335-44 PMID: 22101900 11/22/2011       262 Citations
  • Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. (Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE, Joint Outcome Study Investigators) Gene Ther 2012 Mar;19(3):288-94 PMID: 21697954 06/24/2011       96 Citations
  • In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. (Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC) J Thromb Haemost 2010 Oct;8(10):2224-31 PMID: 20704648 PMCID: PMC3612936 08/14/2010       48 Citations
  • Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII. (Kempton CL, Meeks SL, Donald Harvey R 3rd, Abshire TC) Haemophilia 2011 Jan;17(1):155-6 PMID: 20579112 06/29/2010       8 Citations
  • Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. (Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR) Blood 2010 Jul 15;116(2):280-6 PMID: 20231421 PMCID: PMC2910611 SCOPUS ID: 2-s2.0-77955499972 03/17/2010       98 Citations
  • The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. (Goldenberg NA, Tripputi M, Crowther M, Abshire TC, DiMichele D, Manco-Johnson MJ, Hiatt WR) Contemp Clin Trials 2010 Jan;31(1):131-3 PMID: 19941974 11/28/2009       17 Citations
  • Inhibitors of factor VIII in black patients with hemophilia. (Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE) N Engl J Med 2009 Apr 16;360(16):1618-27 PMID: 19369668 PMCID: PMC2761028 04/17/2009       141 Citations
  • Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment. (Meeks SL, Abshire TC) Haemophilia 2008 Nov;14(6):1159-63 PMID: 19141155 01/15/2009       29 Citations
  • Diagnosis of type 1 VWD: can the clinical history trump laboratory findings? (Abshire TC) Pediatr Blood Cancer 2009 Jan;52(1):7-8 PMID: 19006252 11/14/2008       1 Citation
  • One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. (Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ, Pediatric Rituximab/ITP Study Group, Glaser Pediatric Research Network) Pediatr Blood Cancer 2009 Feb;52(2):259-62 PMID: 18937333 PMCID: PMC5752113 10/22/2008       44 Citations
  • Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. (Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL) N Engl J Med 2007 Aug 09;357(6):535-44 PMID: 17687129 08/10/2007       1203 Citations
  • Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy. (Dunn AL, Abshire TC) Pediatr Blood Cancer 2008 Mar;50(3):627-9 PMID: 17143876 12/05/2006       9 Citations
  • Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. (Kempton CL, Soucie JM, Abshire TC) J Thromb Haemost 2006 Dec;4(12):2576-81 PMID: 17002659 09/28/2006       53 Citations
  • Prophylaxis and von Willebrand's disease (vWD). (Abshire TC) Thromb Res 2006;118 Suppl 1:S3-7 PMID: 16580053 04/04/2006       8 Citations
  • Current issues in prophylactic therapy for persons with hemophilia. (Dunn AL, Abshire TC) Acta Haematol 2006;115(3-4):162-71 PMID: 16549891 03/22/2006       18 Citations
  • Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. (Josephson CD, Abshire TC) Best Pract Res Clin Haematol 2006;19(1):35-49 PMID: 16377540 12/27/2005       11 Citations
  • Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. (Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ) Blood 2006 Apr 01;107(7):2639-42 PMID: 16352811 PMCID: PMC1895391 12/15/2005       170 Citations
  • Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. (Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC) J Thromb Haemost 2005 Jul;3(7):1541-2 PMID: 15978117 06/28/2005       45 Citations
  • Recent advances in the management of the child who has hemophilia. (Dunn AL, Abshire TC) Hematol Oncol Clin North Am 2004 Dec;18(6):1249-76, viii PMID: 15511615 10/30/2004       9 Citations
  • The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. (Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA) Blood 2005 Jan 15;105(2):518-25 PMID: 15383463 09/24/2004       76 Citations
  • Arthroscopic synovectomy for hemophilic joint disease in a pediatric population. (Dunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC) J Pediatr Orthop 2004 Jul-Aug;24(4):414-26 PMID: 15205625 06/19/2004       56 Citations
  • IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. (Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, Angiolillo A, Kulkarni R, Abshire TC, Kelleher J, IGIV-C in ITP Study Group) Thromb Haemost 2004 Apr;91(4):771-8 PMID: 15045139 03/27/2004       48 Citations
  • An approach to the diagnosis and treatment of bleeding disorders in infants. (Abshire TC) Int J Hematol 2002 Aug;76 Suppl 2:265-70 PMID: 12430935 11/15/2002       2 Citations
  • Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. (Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, Key NS, White GC, Lindblad L, Rickles FR, Abshire TC) Hepatology 2002 Oct;36(4 Pt 1):967-72 PMID: 12297845 SCOPUS ID: 2-s2.0-0036789368 09/26/2002       64 Citations
  • Radionuclide synovectomy for hemophilic arthropathy: a comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. (Dunn AL, Busch MT, Wyly JB, Abshire TC) Thromb Haemost 2002 Mar;87(3):383-93 PMID: 11916068 03/28/2002       61 Citations
  • Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. (Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR) Blood 2000 Sep 01;96(5):1709-15 PMID: 10961868 08/29/2000       121 Citations
  • Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. (Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E) Thromb Haemost 2000 Jun;83(6):811-6 PMID: 10896230 07/15/2000       113 Citations
  • Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. (Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM, Findley HW) Leukemia 2000 Jan;14(1):61-7 PMID: 10637478 01/19/2000       74 Citations
  • Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. (Tomer A, Masalunga C, Abshire TC) Am J Hematol 1999 May;61(1):53-61 PMID: 10331512 05/20/1999       41 Citations
  • Coagulopathy in pediatric abusive head trauma. (Hymel KP, Abshire TC, Luckey DW, Jenny C) Pediatrics 1997 Mar;99(3):371-5 PMID: 9041291 03/01/1997       109 Citations
  • Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study. (Bernstein ML, Abshire TC, Pollock BH, Devine S, Toledano S, Steuber CP, Bowman WP, Buchanan GR) J Pediatr Hematol Oncol 1997 Jan-Feb;19(1):68-72 PMID: 9065722 01/01/1997       17 Citations
  • The prolonged thrombin time of nephrotic syndrome. (Abshire TC, Fink LK, Christian J, Hathaway WE) J Pediatr Hematol Oncol 1995 May;17(2):156-62 PMID: 7749766 05/01/1995       6 Citations
  • Prevalence of von Willebrand disease in children: a multiethnic study. (Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC) J Pediatr 1993 Dec;123(6):893-8 PMID: 8229521 12/01/1993       359 Citations
  • Dysfunctional protein C deficiency (type II). A report of 11 cases in 3 American families and review of the literature. (Berdeaux DH, Abshire TC, Marlar RA) Am J Clin Pathol 1993 Jun;99(6):677-86 PMID: 8322701 06/01/1993       14 Citations
  • Philadelphia chromosome-positive chronic myeloid leukemia and thoracic ganglioneuroma. Previously undescribed association. (Shea MP, Abshire TC) Am J Pediatr Hematol Oncol 1993 Feb;15(1):111-4 PMID: 8447551 02/01/1993       3 Citations
  • Relative value of diagnostic studies for von Willebrand disease. (Werner EJ, Abshire TC, Giroux DS, Tucker EL, Broxson EH) J Pediatr 1992 Jul;121(1):34-8 PMID: 1625090 07/01/1992       40 Citations
  • Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. (Abshire TC, Buchanan GR, Jackson JF, Shuster JJ, Brock B, Head D, Behm F, Crist WM, Link M, Borowitz M) Leukemia 1992 May;6(5):357-62 PMID: 1534389 05/01/1992       62 Citations
  • Molecular genetic studies in black families with sickle cell anemia and unusually high levels of fetal hemoglobin. (Seltzer WK, Abshire TC, Lane PA, Roloff JS, Githens JH) Hemoglobin 1992;16(5):363-77 PMID: 1385360 01/01/1992       10 Citations
  • Severe neonatal protein C deficiency: prevalence and thrombotic risk. (Manco-Johnson MJ, Abshire TC, Jacobson LJ, Marlar RA) J Pediatr 1991 Nov;119(5):793-8 PMID: 1834822 11/01/1991       73 Citations
  • The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? (Abshire TC, Gold SH, Odom LF, Carson SD, Hathaway WE) Cancer 1990 Aug 15;66(4):716-21 PMID: 2386901 08/15/1990       31 Citations
  • Zinc status in children and young adults with sickle cell disease. (Abshire TC, English JL, Githens JH, Hambidge M) Am J Dis Child 1988 Dec;142(12):1356-9 PMID: 3195534 12/01/1988       10 Citations
  • Anemia of acute inflammation in children. (Abshire TC, Reeves JD) J Pediatr 1983 Dec;103(6):868-71 PMID: 6644420 12/01/1983       35 Citations
  • Last update: 01/21/2020
    jenkins-FCD Prod-480 9a4deaf152b0b06dd18151814fff2e18f6c05280